Optimizing bioprocess purification: effective nucleic acid removal in high salt environments

As the field of cell and gene therapies rapidly advances, ensuring the purity and safety of biologics is more critical than ever. Regulatory standards set by the US FDA and other global agencies emphasize the need for purification methods that effectively remove host cell nucleic acid impurities, particularly chromatin-associated DNA.

A significant challenge in achieving high purity levels is the disruption of the robust chromatin structure. Traditional methods using salt-inactive endonucleases often struggle to meet the stringent regulatory limit of 10 ng/dose for residual host DNA, especially with DNA fragments smaller than 200 bp. Recent developments of advanced salt-active endonucleases are helping to address these challenges. Saltonase, an advanced salt-active endonuclease, is effective at physiological pH levels and pH 8.5 and above. It maintains stability under challenging conditions, and its robust digestion capabilities makes it highly efficient at removing nucleic acid impurities.

This webinar will explore advancing bioprocess purification workflows using salt-active endonucleases. We will further discuss case studies and applications that highlight the improved purification efficiency and safety achieved using advanced endonuclease technology.

Attend this webinar to:

• Understand the difficulties posed by chromatin-associated DNA in purification processes and why traditional salt-inactive endonucleases often fail to successfully remove host DNA impurities.
• Discover the benefits of a novel salt-active endonuclease that maintains stability and effectiveness across a wide range of pH levels.
• Explore the ways in which advanced endonucleases can be integrated into existing bioprocess workflows to enhance nucleic acid removal.

Joanna Niska-Blakie

Global Product Manager at QIAGEN

Dr Joanna Niska-Blakie completed her Master's research study on telomeres at École Normale Supérieure de Lyon and earned a PhD in cancer research from the FIRC Institute for Molecular Oncology in Milan in 2013. Later, during her postdoctoral work at A*STAR in Singapore, she focused on oncology and the gut microbiome. Currently, Joanna strategically manages the Biopharma Enzymes portfolio at QIAGEN. In this role, she oversees new enzyme development dedicated to advancing biopharmaceutical solutions in the cell and gene therapy field.

Eleonora Turco

Director, R&D Enzymes at QIAGEN

Dr. Eleonora Turco earned her PhD from Max Perutz Labs Vienna in 2015, where she specialized in histone ubiquitination. She then was a postdoctoral fellow at the University of Vienna, conducting research on autophagy. Following her postdoc, Eleonora became a Senior Principal Scientist and Functional Lead at Novartis, where she led the Manufacturing Science & Technology downstream development lab. She is currently the Director of R&D Enzymes at QIAGEN.

With a deep expertise in molecular and cellular biology, Eleonora brings extensive experience to the field of bioprocess purification.

in 27

Days

Register

SPEAKERS

Joanna Niska-Blakie

Global Product Manager at QIAGEN

Eleonora Turco

Director, R&D Enzymes at QIAGEN

You might also like

Development of an automated AAV capsid titer assay on a high-throughput platform

Matthew J.Lotti, John Chappell

3 September

in 39

Days

Register

Quickly and accurately measure key analytical attributes of viral vectors with macro mass photometry

Laura Pala

29 August

in 34

Days

Register

Extracellular vesicles: setting-up the path to IND with advanced characterization packages

Davide Zocco

28 August

in 33

Days

Register

Engineering next-generation CAR-T cell therapy for cancer

Yvonne Chen

21 August

in 26

Days

Register

Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

Nikki Votaw

20 August

in 25

Days

Register